Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Applied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trial

5 August 2026 · By · Wire by Fusion42

Published

5 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at streetinsider.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

Applied Biologics has received central IRB approval for their Phase 3 BIOxHEAL clinical trial targeting nonhealing diabetic foot ulcers, allowing clinical site activation and patient enrollment to begin soon in the United States.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You in biotech clinical development now have a clearer path to enrolling patients and advancing therapies for chronic wounds. This regulatory nod opens the door for quicker trial execution but puts a premium on rapid site activation and managing enrolment efficiency.

◆ Coverage

1 source · 5 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialbiotechregulatory-approvalphase-3medical-device